EP3700936A4 - ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES - Google Patents

ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES Download PDF

Info

Publication number
EP3700936A4
EP3700936A4 EP17929557.1A EP17929557A EP3700936A4 EP 3700936 A4 EP3700936 A4 EP 3700936A4 EP 17929557 A EP17929557 A EP 17929557A EP 3700936 A4 EP3700936 A4 EP 3700936A4
Authority
EP
European Patent Office
Prior art keywords
glyco
muc1 antibodies
muc1
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17929557.1A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3700936A1 (en
Inventor
Thayer White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Go Therapeutics Inc
Original Assignee
Go Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Go Therapeutics Inc filed Critical Go Therapeutics Inc
Publication of EP3700936A1 publication Critical patent/EP3700936A1/en
Publication of EP3700936A4 publication Critical patent/EP3700936A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
EP17929557.1A 2017-10-24 2017-10-24 ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES Pending EP3700936A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/058036 WO2019083506A1 (en) 2017-10-24 2017-10-24 ANTI-GLYCO-MUC1 ANTIBODIES AND USES THEREOF

Publications (2)

Publication Number Publication Date
EP3700936A1 EP3700936A1 (en) 2020-09-02
EP3700936A4 true EP3700936A4 (en) 2021-05-26

Family

ID=66247577

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17929557.1A Pending EP3700936A4 (en) 2017-10-24 2017-10-24 ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES

Country Status (10)

Country Link
EP (1) EP3700936A4 (enExample)
JP (2) JP7358367B2 (enExample)
KR (2) KR102832078B1 (enExample)
CN (1) CN111479828B (enExample)
AU (1) AU2017436815B2 (enExample)
BR (1) BR112020008001A2 (enExample)
CA (1) CA3078812A1 (enExample)
IL (1) IL274202A (enExample)
MX (1) MX2020004220A (enExample)
WO (1) WO2019083506A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020008001A2 (pt) * 2017-10-24 2020-10-20 Go Therapeutics, Inc. anticorpo anti-glico-muc1 ou fragmento de ligação de antígeno, proteína de fusão, receptor de antígeno quimérico, conjugado de anticorpo-fármaco, ácido nucleico, vetor, célula hospedeira, composição farmacêutica, e, métodos de tratar câncer e de detectar câncer em uma amostra biológica.
IL300104A (en) * 2020-07-31 2023-03-01 Scherer Technologies Llc R P Antibody specific for mucin-1 and methods of using it
CA3230370A1 (en) * 2021-08-27 2023-03-02 Peptron, Inc. Novel anti-muc1 antibody and use thereof
CA3241162A1 (en) * 2021-12-21 2023-06-29 Rinse KLOOSTER Binding domains against cancer-associated muc1
CN115068610B (zh) * 2022-01-27 2024-04-16 中国农业大学 抑制乳腺癌细胞中muc1表达的物质在降低抗乳腺癌药物耐药性中的应用
TW202444432A (zh) * 2023-04-13 2024-11-16 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｅｇｆｒ和ｍｕｃ１的抗原結合分子、其藥物偶聯物及其醫藥用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150005474A1 (en) * 2003-01-23 2015-01-01 Glycotope Gmbh Recognition molecules for the treatment and detection of tumors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020146750A1 (en) * 2000-03-30 2002-10-10 Hoogenboom Hendricus R.J.M. Mucin-1 specific binding members and methods of use thereof
AU2007304590A1 (en) * 2006-10-04 2008-04-10 Cancer Research Technology Limited Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
EP2014302A1 (en) * 2007-07-12 2009-01-14 Institut Curie An antibody specific for the Tn antigen for the treatment of cancer
CN101978054B (zh) * 2007-12-05 2013-05-29 协和发酵麒麟株式会社 能够与肝素结合性表皮生长因子样生长因子结合的单克隆抗体
CN102264765B (zh) * 2008-10-28 2016-01-20 盐野义制药株式会社 抗muc1抗体
EP2281844A1 (en) * 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015120180A1 (en) * 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
AU2015254257B2 (en) * 2014-04-28 2021-02-25 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof
BR112020008001A2 (pt) * 2017-10-24 2020-10-20 Go Therapeutics, Inc. anticorpo anti-glico-muc1 ou fragmento de ligação de antígeno, proteína de fusão, receptor de antígeno quimérico, conjugado de anticorpo-fármaco, ácido nucleico, vetor, célula hospedeira, composição farmacêutica, e, métodos de tratar câncer e de detectar câncer em uma amostra biológica.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150005474A1 (en) * 2003-01-23 2015-01-01 Glycotope Gmbh Recognition molecules for the treatment and detection of tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1993, FONTENOT: "Synthesis of large multideterminant peptide immunogens using a poly-proline beta-turn helix motif", XP055796187, Database accession no. PREV199497079884 *

Also Published As

Publication number Publication date
WO2019083506A1 (en) 2019-05-02
KR20200067885A (ko) 2020-06-12
EP3700936A1 (en) 2020-09-02
CA3078812A1 (en) 2019-05-02
JP2021510307A (ja) 2021-04-22
KR20230165874A (ko) 2023-12-05
KR102608763B1 (ko) 2023-11-30
JP2024001073A (ja) 2024-01-09
KR102832078B1 (ko) 2025-07-08
CN111479828A (zh) 2020-07-31
AU2017436815A1 (en) 2020-04-23
AU2017436815B2 (en) 2025-05-29
MX2020004220A (es) 2020-10-05
IL274202A (en) 2020-06-30
JP7358367B2 (ja) 2023-10-10
BR112020008001A2 (pt) 2020-10-20
CN111479828B (zh) 2024-07-05

Similar Documents

Publication Publication Date Title
EP3625263A4 (en) ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
EP3891183A4 (en) ANTI-CLAUDIN ANTIBODIES AND USES THEREOF
EP3759143A4 (en) ANTI-TIGIT ANTIBODIES AND USES THEREOF
EP3383916A4 (en) Anti-cd73 antibodies and uses thereof
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3389702A4 (en) ANTI-LAG-3 ANTIBODIES AND USES THEREOF
MA49683A (fr) Anticorps anti-cd8 et leurs utilisations
EP3504243A4 (en) ANTI-TIM-3 ANTIBODIES AND USE THEREOF
EP3661965A4 (en) ANTI-CD47 ANTIBODIES AND USES THEREOF
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
EP3426288A4 (en) ANTI-PACAP ANTIBODIES AND USES THEREOF
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3328895A4 (en) ANTI-PD-1 ANTIBODIES AND USES THEREOF
EP3645563A4 (en) ANTI-FAM19A5 ANTIBODIES AND USES THEREOF
EP3283517A4 (en) ANTI-PACAP ANTIBODIES AND USES THEREOF
EP3383904A4 (en) CTLA-4 ANTIBODIES AND USES THEREOF
EP3790586A4 (en) ANTI-DLL3 ANTIBODIES AND USES THEREOF
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
EP3672987A4 (en) ANTI-APELIN ANTIBODIES AND USES THEREOF

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200521

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40025649

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210429

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/30 20060101AFI20210422BHEP

Ipc: G01N 33/574 20060101ALI20210422BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS